Mobile Health for Adherence in Breast Cancer Patients (NCT06112613)

🧪 Interventions in This Study

• Electronic Health Record Review (OTHER)
• Health Promotion and Education (OTHER)
• Health Telemonitoring (PROCEDURE)
• Patient Navigation (BEHAVIORAL)
• Survey Administration (OTHER)
• Text Message-Based Navigation Intervention (OTHER)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. PATIENT STEP 0: Patient must be \>= 18 years of age
2. PATIENT STEP 0: Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish
3. PATIENT STEP 0: Patient must present with new or established breast cancer at the time of Step 0
4. PATIENT STEP 0: Patient must have initiated any of the CKD4/6 inhibitors (palbociclib or Ibrance, ribociclib or Kisqali, abemaciclib or Verzenio) within 60 days prior to registration to Step 0 or have received a prescription order with stated intent to initiate within 30 days following registration to Step 0
5. NOTE: Patients who have been treated previously with anticancer treatments other than CDK4/6 inhibitors are eligible
6. NOTE: CDK4/6 inhibitors must be provided/supplied as a single agent blister pack. If the medication is supplied as capsules in a pill bottle (e.g., Ibrance capsules), patient is not eligible
7. NOTE: Ribociclib (Kisqali) and abemaciclib (Verzenio) are only available in blister packs. Palbociclib (Ibrance) is the only CDK4/6 inhibitor that might be available in a capsule formulation. However, this is an outdated formulation and is rarely prescribed as a new start. The format of ordered palbociclib can be determined based on the prescription order
8. PATIENT STEP 0: Patient must not have been previously treated with any of the following CDK4/6 inhibitors: Palbociclib or Ibrance, ribociclib or Kisqali, and abemaciclib or Verzenio
9. PATIENT STEP 0: Patient must not already be enrolled in a therapeutic clinical trial that monitors CDK4/6 inhibitors
10. PATIENT STEP 0: Patient must not be enrolled in a symptom science clinical trial that monitors or intervenes on symptoms related to CDK4/6 inhibitors
11. NOTE: If NRG-CC012CD is activated in a participating practice, and a patient meets the eligibility criteria for both EAQ221CD and NRG-CC012CD, then EAQ221CD should be offered first to patients. Only if a patient is not eligible or not interested in participating in EAQ221CD, the NRG-CC012CD can be offered
12. PATIENT STEP 0: Patient must confirm that they intend to receive their care or monitoring at a National Cancer Institute Community Oncology Research Program (NCORP) site or one of the following two NCI designated Comprehensive Cancer Centers: Emory University Winship Cancer Institute or University of California Irvine Chao Family Comprehensive Cancer Center

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (506 Sites)

Showing the first 25 of 506 sites.

• Fairbanks Memorial Hospital — Fairbanks, Alaska
• Kingman Regional Medical Center — Kingman, Arizona
• Cancer Center at Saint Joseph's — Phoenix, Arizona
• Mercy Hospital Fort Smith — Fort Smith, Arkansas
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
• CARTI Cancer Center — Little Rock, Arkansas
• Kaiser Permanente-Anaheim — Anaheim, California
• Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
• PCR Oncology — Arroyo Grande, California
• Kaiser Permanente-Baldwin Park — Baldwin Park, California
• Kaiser Permanente-Bellflower — Bellflower, California
• Mercy Cancer Center - Carmichael — Carmichael, California
• Mercy San Juan Medical Center — Carmichael, California
• Mercy Cancer Center - Elk Grove — Elk Grove, California
• Kaiser Permanente-Fontana — Fontana, California
• Kaiser Permanente South Bay — Harbor City, California
• Kaiser Permanente-Irvine — Irvine, California
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
• Kaiser Permanente West Los Angeles — Los Angeles, California
• Contra Costa Regional Medical Center — Martinez, California
• Mercy Cancer Center — Merced, California
• Kaiser Permanente-Ontario — Ontario, California
• UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
• Kaiser Permanente - Panorama City — Panorama City, California
• Kaiser Permanente-Riverside — Riverside, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Carcinoma

• 3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer — Rochester, Minnesota
• Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital — Columbus, Ohio
• Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer — Rochester, Minnesota
• Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer — Scottsdale, Arizona
• An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction — Houston, Texas

Explore by condition: All Breast Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.